Effects of peroral levosimendan in the prevention of further hospitalisations in patients with chronic heart failure. A randomised, double-blind, placebo-controlled, multi-centre, parallel-group study

Update Il y a 4 ans
Reference: EUCTR2004-004225-10

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Primary objective is to test the hypothesis that levosimendan is superior to placebo in the composite endpoint called “Patient Journey” during the 60 days following randomisation.


Inclusion criteria

  • Cardiac Failure